Floatz logo

Prgn-2009

Oropharyngeal Carcinoma

National Cancer Institute (NCI)vaccinePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Oropharyngeal Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
HRYZ Biotech Co.
Phase 2BB
Fludarabine
HRYZ Biotech Co.
Phase 2BB
Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2B
Cis-Diamminedichloroplatinum Ii
Loren Mell, MD
Phase 2B
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
National Cancer Institute (NCI)
Phase 2B

View all 23 →

Same molecule, other indications

Prgn-2009 is also rated in:

reproductive system cancerActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
anal carcinomaActive
CC
Indicative · Phase 1/2
43 / 100
View asset →
cervical cancerActive
CC
Indicative · Phase 1/2
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →